Search

Faricimab

[L40026] It received subsequent approval for the same indications in Canada in May 2022. … [L43085] On April 9, 2026, the FDA approved an updated label that extended faricimab treatment for macular edema following retinal vein occlusion (RVO) beyond six months.[L40026]

Ecabet

Ecabet is currently marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis.

Fexapotide

NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed.

Teprotumumab

[L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was … approved by the FDA in January 2020 for the treatment of TED.

Tiludronic acid

[A1923] Tiludronic acid was first described in the literature in 1988 as a potential treatment for Paget's disease of bone.[A202235] Tiludronic acid was granted FDA approval on 7 March 1997.[L4763]

Levonordefrin

Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.

Ingenol mebutate

Before approval, ingenol mebutate was called PEP005 as an investigational drug. … PEP005 also has potent anti-leukemic effects, inducing apoptosis in myeloid leukemia cell lines and primary AML cells at nanomolar concentrations.

Saprisartan

Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure.

Suprofen

An ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.

Light mineral oil